SEC News
Repare Therapeutics Inc (RPTX)
New Form 25-NSE - Repare Therapeutics Inc. <b>Filed:</b> 2026-01-28 <b>AccNo:</b> 0001354457-26-000100 <b>Size:</b> 3 KB
FDA Approval
FDA approves LAMOTRIGINE from TORRENT
Final approval of ANDA #ANDA #217100 for LAMOTRIGINE. Decision date: 01/08/2026
About Us
The main activity of our team is the prompt receipt of open information from various sources in order to analyze the market reaction to this information.
Our strategies:
- a combination of various open sources of information with the identification and use of those that provide information most quickly;
- extracting information mainly by automatic means using artificial intelligence;
- providing users with structured information with modern available development tools;
- the use of approaches and tools of machine learning methods to identify the most important events that affect the market;